

Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
Out of StockSize
Quantity
Bundle & Save
Restock alert
Notify me when it’s back
Quality & methods
Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C225H348N48O68
Molecular weight
~4,810.5 g/mol
CAS number
2023788-19-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib at positions 2 and 13; Lys20 acylated with a C20 fatty-diacid via a spacer linker; modifications confer protease resistance and albumin binding.
A 39-residue synthetic peptide. Two Aib residues at positions 2 and 13 confer protease resistance; the C20 fatty-diacid chain on Lys20, attached via a spacer, promotes reversible albumin binding and extends the peptide's circulating half-life. Signaling studies characterize its engagement of class B1 G protein–coupled receptors, including Gαs–cAMP coupling and receptor internalization behavior.
Lyophilized
20°C (-80°C long term)
lyophilized powder stable ~3 years.
Prepare stock solutions fresh; protect from light; keep sealed and dry.
Reviews
Galindo RJ, et al. (2025). Diabetes Therapy
Zhou Q, et al. (2023). Diabetology & Metabolic Syndrome
Reviews
Reviews reflect individual research observations only. All products are for research use only — not for human consumption.
No reviews yet. Be the first to share your research observations.
Purchased this? Leave a review from your account.
Reviews
Min T, et al. (2021). Diabetes Ther
Forzano I, et al. (2022). Int J Mol Sci
Tang Y, et al. (2022). Front Pharmacol
Lin F, et al. (2023). PLoS One
Clinical
Thomas MK, et al. (2021). J Clin Endocrinol Metab
Rosenstock J, et al. (2021). Lancet
Frías JP, et al. (2021). N Engl J Med
Ludvik B, et al. (2021). Lancet
Primary research
Rees TA, et al. (2024). Frontiers in Pharmacology
Zhao F, et al. (2022). Nature Communications
Sun W, et al. (2022). Proceedings of the National Academy of Sciences
Willard FS, et al. (2020). JCI Insight
Heise T, et al. (2022). Lancet Diabetes Endocrinol
Jastreboff AM, et al. (2022). N Engl J Med
Loomba R, et al. (2024). N Engl J Med
Malhotra A, et al. (2024). N Engl J Med
Packer M, et al. (2025). N Engl J Med
Coskun T, et al. (2018). Molecular Metabolism
El K, et al. (2023). Nat Metab